Please scroll down to see the issues we are working on

VAC-AVC was founded to strengthen patient care and provide patients, caregivers, families and healthcare professionals with a place to learn and meet. We are always keen to find out which questions about the care for vascular anomalies we should be helping to answer.

Please help us by downloading documents we share here and sending your ideas and suggestions to Wendy Moss, Director at Large Patient Support and Advocacy at wendy.moss@cw.ba.ca. Thank you.

The announcement by Novartis of the withdrawal of the Managed Access Program (MAP) for Alpelisib means there is no way for patients to have ongoing access to this treatment in Canada. Niina Kleiber, CHU Ste Justine and VAC Secretary, Kelley Zwicker, CHEO Ottawa, initiated a survey to determine how, when and why Alpelisib is being prescribed to advocate for ongoing access.

You can view the results below.